Jennifer Jarrett Acquires Shares in Sagimet Biosciences Inc.
Jennifer Jarrett purchased 39,567 shares of Sagimet Biosciences on June 12, 2026.
Key Points
- Jennifer Jarrett bought 39,567 shares of Sagimet Biosciences Inc. (SGMT) on June 12, 2026.
- Sagimet Biosciences, trading at $6.48, has a market cap of $399.5 million and no meaningful P/E as it isn't profitable.
- Analysts maintain a positive outlook with a mean price target of $26.20, supported by recent insider buying.
On June 12, 2026, Jennifer Jarrett made a notable move by purchasing 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT). This acquisition was not part of a pre-planned trading program and occurred at a time when the stock was trading at $6.48 per share.
Insider Buying and Selling at Sagimet Biosciences Inc.
In addition to Jennifer Jarrett, other insiders including Beth Seidenberg, Paul Hoelscher, Elizabeth Grammer, Anne Phillips, and George Kemble each bought 39,567 shares on the same day. These transactions were not part of any pre-arranged trading plans.
Other Institutional Activity in Sagimet Biosciences
Several institutional investors have also shown interest in Sagimet Biosciences. Vanguard Capital Management LLC added 1,098,919 shares, bringing its total to 1,098,919 shares valued at approximately $5.74 million. Marshall Wace, LLP increased its holdings by 185,807 shares, ending with 966,253 shares worth about $5.04 million. Meanwhile, Affinity Asset Advisors, LLC reduced its position by 280,225 shares, now holding 868,020 shares valued at $4.54 million.
Sagimet Biosciences Inc. Stock Snapshot
Shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) are currently trading near $6.48. The company has a market capitalization of $399.5 million. Although it is not profitable, it has a forward P/E ratio of -4.93. The stock has experienced a 52-week low of $4.50 and a high of $11.41. The firm maintains a strong liquidity position with a current ratio of 20.34 and a quick ratio of 19.74, alongside a very low debt-to-equity ratio of 0.038.
Analysts Set New Price Targets
Analysts have been optimistic about Sagimet Biosciences' prospects. On May 19, 2026, Citizens maintained a 'buy' rating with a $12.00 price target. Earlier, on May 4, 2026, Canaccord Genuity reiterated its 'buy' rating, setting a target of $49.00. The consensus among analysts is a 'buy', with a mean price target of $26.20 based on 10 analyst opinions.
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California. It focuses on developing novel therapeutics known as fatty acid synthase (FASN) inhibitors to treat diseases associated with metabolic and fibrotic pathways. Its leading drug candidate, Denifanstat, targets conditions such as metabolic dysfunction-associated steatohepatitis, acne, and certain cancers. The company, led by CEO David A. Happel, was originally named 3-V Biosciences, Inc. before rebranding in August 2019.
Bottom Line
Jennifer Jarrett's purchase of Sagimet Biosciences shares highlights insider confidence in the company's future. With a strong market position and a promising pipeline, Sagimet continues to attract attention from both insiders and analysts. As always, remember that insider transactions are disclosed after the fact and reflect past actions rather than future intentions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.